Closing in on HIV drug resistance.

Closing in on HIV drug resistance.

The structure of a catalytic complex of HIV-1 reverse transcriptase helps rationalize resistance mechanisms for nucleoside analog drugs.

Bibliographic Details
Main Authors:	Larder, B, Stammers, D
Format:	Journal article
Language:	English
Published:	1999

Similar Items

Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.
by: Lennerstrand, J, et al.
Published: (2001)

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.
by: Ren, J, et al.
Published: (1998)

Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.
by: Lennerstrand, J, et al.
Published: (2001)

HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance.
by: Ren, J, et al.
Published: (2005)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
by: Ren, J, et al.
Published: (2008)

HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.
by: Lowe, D, et al.
Published: (1988)

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
by: Ren, J, et al.
Published: (2000)

Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.
by: Hopkins, A, et al.
Published: (1999)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
by: Hopkins, A, et al.
Published: (2004)

Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors.
by: Tisdale, M, et al.
Published: (1989)

Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.
by: Chamberlain, P, et al.
Published: (2002)

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
by: Harrigan, P, et al.
Published: (2002)

Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
by: Ren, J, et al.
Published: (2006)

HIV and Drug-Resistant Subtypes
by: Bianca Maria Nastri, et al.
Published: (2023-01-01)

Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
by: Ren, J, et al.
Published: (2001)

The Russian database of HIV antiretroviral drug resistance
by: Dmitry E. Kireev, et al.
Published: (2023-05-01)

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance
by: Charlotte Charpentier, et al.
Published: (2023-02-01)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
by: Freeman, G, et al.
Published: (2004)

THE GROWTH AND CHARACTERIZATION OF CRYSTALS OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) REVERSE-TRANSCRIPTASE
by: Jones, E, et al.
Published: (1993)

HIV drug resistance: past and current trends
by: Ekaterina N. Ozhmegova, et al.
Published: (2022-09-01)

Tuberculosis Drug Resistance and HIV Infection, the Netherlands
by: Catharina Hendrika Haar, et al.
Published: (2007-05-01)

Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
by: Ren, J, et al.
Published: (2008)

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.
by: Larder, B, et al.
Published: (1999)

Experience in treating drug-resistant tuberculosis in patients with HIV infection
by: A. I. Gordon, et al.
Published: (2014-12-01)

Recommendations on data sharing in HIV drug resistance research.
by: Seth C Inzaule, et al.
Published: (2023-09-01)

The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns.
by: Marks, A, et al.
Published: (2010)

PREVALENCE OF DRUG RESISTANT HIV STRAINS IN HIV-INFECTED PATIENTS OF REPRODUCTIVE AGE
by: N. Babii
Published: (2017-09-01)

The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns
by: Marks, A, et al.
Published: (2010)

Genetic diversity and drug resistance mutations of HIV-1 in Leningrad Region
by: A. N. Shchemelev, et al.
Published: (2022-03-01)

HIV-1 drug resistance in primary infections in the UK.
by: Fidler, S, et al.
Published: (2001)

Drug-resistant HIV increasing, UK study finds
by: Karen Birmingham

Current Perspectives on HIV-1 Antiretroviral Drug Resistance
by: Pinar Iyidogan, et al.
Published: (2014-10-01)

Transmitted and acquired HIV drug resistance in Viet Nam
by: Thao, V
Published: (2015)

Next-generation sequencing and HIV drug resistance surveillance
by: Hamers, R, et al.
Published: (2016)

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.
by: Ren, J, et al.
Published: (2002)

Drug resistance and drug resistance gene analysis for 205 cases of pulmonary tuberculosis with HIV-infected patients
by: Ge LI, et al.
Published: (2022-12-01)

HIV REVERSE-TRANSCRIPTASE MUTATION ENABLES EVASION OF CTL MEDIATED IMMUNITY
by: Meier, U, et al.
Published: (1995)

Prediction and inference of dynamics in quantum plasmas
by: Larder, B
Published: (2020)

Inhibition of HIV-1 reverse transcriptase by defined template/primer DNA oligonucleotides: effect of template length and binding characteristics.
by: Idriss, H, et al.
Published: (1994)

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
by: Ren, J, et al.
Published: (2004)